This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the latest trading session, Medpace (MEDP) closed at $350.37, marking a +1.83% move from the previous day.
Elevance Health's Q4 Earnings Beat Estimates on Rising Premiums
by Zacks Equity Research
ELV's fourth-quarter results benefit from rising premiums. However, higher expenses and attrition in Medicaid membership partially offset the positives.
Here's Why You Should Add Ensign Stock to Your Portfolio Now
by Zacks Equity Research
ENSG's valuation looks relatively cheap compared with the industry average.
Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?
by Zacks Equity Research
Here is how Alnylam Pharmaceuticals (ALNY) and Medpace (MEDP) have performed compared to their sector so far this year.
Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSMD
Mixed Bag for UnitedHealth: Q4 Earnings Beat, Revenues Fall Short
by Zacks Equity Research
UNH projects revenues between $450 billion and $455 billion for 2025.
Centene Expands Care in Hawaii With a Residential Program
by Zacks Equity Research
CNC's 'Ohana Health Plan joins forces with Hope Services Hawaii to launch a residential program offering integrated clinical care for members facing homelessness and complex health needs.
Teladoc Partners With Amazon to Expand Chronic Care Program Reach
by Zacks Equity Research
TDOC collaborates with Amazon to enhance its reach for chronic condition management programs.
MultiPlan (MPLN) Soars 15.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
MultiPlan (MPLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Why Medpace (MEDP) Outpaced the Stock Market Today
by Zacks Equity Research
Medpace (MEDP) closed the most recent trading day at $352.01, moving +0.32% from the previous trading session.
Bet on 5 Top-Ranked Stocks With Rising P/E to Boost Your Portfolio
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Constellation Brands, Edgewell Personal Care, Rent the Runway, Medpace and Canoo.
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Medpace (MEDP) stood at $346.81, denoting a +1.39% change from the preceding trading day.
Medpace (MEDP) Stock Moves -0.33%: What You Should Know
by Zacks Equity Research
The latest trading day saw Medpace (MEDP) settling at $332.23, representing a -0.33% change from its previous close.
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Medpace (MEDP) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Medpace (MEDP) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Medpace (MEDP) closed the most recent trading day at $339.05, moving +0.52% from the previous trading session.
Medpace (MEDP) Stock Moves -0.36%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Medpace (MEDP) stood at $348.48, denoting a -0.36% change from the preceding trading day.
PACS vs. MEDP: Which Stock Is the Better Value Option?
by Zacks Equity Research
PACS vs. MEDP: Which Stock Is the Better Value Option?
Medpace (MEDP) Tops Q3 Earnings Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 8.66% and 1.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Rises Higher Than Market: Key Facts
by Zacks Equity Research
In the most recent trading session, Medpace (MEDP) closed at $347.91, indicating a +0.93% shift from the previous trading day.
Medpace (MEDP) Laps the Stock Market: Here's Why
by Zacks Equity Research
Medpace (MEDP) reachead $343.05 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
SOLV or MEDP: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SOLV vs. MEDP: Which Stock Is the Better Value Option?
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, Medpace (MEDP) closed at $326.26, marking a +1.77% move from the previous day.
Medpace (MEDP) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
The latest trading day saw Medpace (MEDP) settling at $354.65, representing a -0.57% change from its previous close.
Is Medpace (MEDP) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Medpace (MEDP). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?